Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heart rhythm showdown: which ablation strategy wins for persistent AF?

NCT ID NCT05921734

Disease control Sponsor: Shanghai Chest Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tested two ways to treat persistent atrial fibrillation (a type of irregular heartbeat) using catheter ablation. In one group, doctors aimed to stop the abnormal rhythm during the procedure. In the other, they followed a preset plan and used electrical shock if needed. The trial included 480 adults having their first ablation. The goal was to see which approach led to fewer heart rhythm problems over 12 months.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
catheter ablation procedure
What this could lead to
If successful, this could help doctors choose the best ablation approach to reduce irregular heart rhythms in people with persistent atrial fibrillation.
What could go wrong
The trial is completed but results are not yet widely published. Ablation carries risks like bleeding, infection, or heart damage, and the best strategy may still depend on individual patient factors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

480 people

The number who actually took part.

Started

Aug 2023

Finished

Aug 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. . Age 18-80 years old. 2. . Patients undergoing a first-time ablation procedure for PersAF. 3. . Diagnosed as persistent AF according to the latest clinical guidelines. 4. . Ineffective or intolerable to ≥1 anti-arrhythmia drug treatment. 5. . Patients must be able and willing to provide written informed consent to participate in this study. Exclusion Criteria: 1. . Uncontrolled congestive heart failure; 2. . History of severe valve disease and/or prosthetic valve replacement; 3. . Myocardial infarction or stroke within 6 months; 4. . Severe congenital heart disease; 5. . EF \<35%; 6. . Contrast agent allergy; 7. . The use of anticoagulant drugs is contraindicated; 8. . Severe lung disease; 9. . Left atrial thrombus confirmed by preoperative esophageal ultrasound; 10. . Contraindications for cardiac catheterization; 11. . Prior left atrial ablation (surgical or catheter); 12. . Have performed any cardiac surgery within 2 months; 13. . Poor general health; 14. . Life expectancy \< 12 months.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atrial fibrillation are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

atrial fibrillation persistent atrial fibrillation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Atrial fibrillation Cathter ablation Endpoint

Contacts and locations

Locations

  • Mu Qin

    Shanghai, 200030, China

  • Shanghai Chest Hospital

    Shanghai, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.